A Single-arm Phase I Clinical Study of TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Latest Information Update: 14 Oct 2025
At a glance
- Drugs GT 101 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GRIT Biotechnology
Most Recent Events
- 29 Sep 2025 Planned number of patients changed from 20 to 12.
- 29 Sep 2025 Planned End Date changed from 21 Apr 2024 to 31 Dec 2027.
- 29 Sep 2025 Planned primary completion date changed from 21 Apr 2024 to 31 Dec 2027.